Intensified glycemic control is now recommended as the standard of care for all patients with diabetes. Unfortunately, the major barrier to achieving normoglycemia in patients with diabetes is hypoglycemia. Further complicating management of patients with diabetes is that the therapeutic cornerstone of exercise also contributes to increased hypoglycemia. Many studies have identified that intensive glycemic control can result in acquired failure of neuroendocrine and importantly autonomic nervous system (ANS) counterregulatory responses during hypoglycemia. Recent work has also demonstrated that episodes of both antecedent hypoglycemia and exercise can result in reciprocal, subsequent ANS counterregulatory dysfunction during either stress. The mechanisms responsible for prior hypoglycemia and/or exercise resulting in ANS counterregulatory dysfunction have yet to be determined. Recent interest has begun to be focused on central nervous system (CNS) regulation of physiologic responses during exercise and hypoglycemia. Currently, there are no adjunct treatments that protect the ANS from the deleterious effects of repeated episodes of hypoglycemia. In this application, we will propose therapeutic interventions aimed at reversing the central mechanisms that result in hypoglycemia associated autonomic dysfunction (HAAD). Atherothrombosis is a major cause of morbidity and mortality in patients with type 2 diabetes (T2DM). Recent large clinical trials have highlighted the association between hypoglycemia and increased mortality in T2DM. Of concern is the lack of information regarding the physiologic effects of ANS activation on endothelial function and atherothrombofic balance during hypoglycemia in diabefic individuals. Studies oufiined in this proposal are therefore focused at determining the in-vivo mechanisms regulating ANS counterregulatory responses and in-vivo vascular and metabolic effects during hypoglycemia and exercise in healthy and diabefic humans. Experiments will use the glucose and pancreafic clamp techniques to control glucose levels and glucoregulatory hormones. ANS responses to hypoglycemia will be assessed by measuring circulating catecholamines, pancreatic polypepfide, muscle sympathefic nerve acfivity (MSNA), symptom scores and heart rate variability. Neuroendocrine responses will be determined by measuring growth hormone, Cortisol and glucagon levels. Metabolic counterregulatory mechanisms will be quantified by measuring glucose turnover, lipolysis and substrate oxidafion via indirect calorimetry. Nitric oxide and non-nitric oxide dependent endothelial arterial funcfion will be determined by flow mediated vasodilafion, vascular atherothrombotic balance will be determined by PAl-1, TPA, P-selecfin and adhesion molecule levels.

Public Health Relevance

Cardiovascular disease is a major cause of morbidity and mortality in individuals with diabetes. Recently, large multi-center randomized controlled trials have reported an associafion between hypoglycemia and serious cardiovascular events and death in type 2 diabetes. This application will determine in-vivo mechanisms responsible for hypoglycemia associated adverse cardiac events and propose novel treatments to prevent this occurrence.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
2P01HL056693-16
Application #
8293462
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
16
Fiscal Year
2012
Total Cost
$299,355
Indirect Cost
$14,000
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Mar, Philip L; Raj, Satish R (2018) Orthostatic hypotension for the cardiologist. Curr Opin Cardiol 33:66-72
Chaugai, Sandip; Dickson, Alyson L; Shuey, Megan M et al. (2018) Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. Clin Pharmacol Ther :
van den Berg, Maarten P; Almomani, Rowida; Biaggioni, Italo et al. (2018) Mutations in CYB561 Causing a Novel Orthostatic Hypotension Syndrome. Circ Res 122:846-854
Kaufman, Melissa R; Chang-Kit, Laura; Raj, Satish R et al. (2017) Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourol Urodyn 36:610-613
Shaw, Brett H; Garland, Emily M; Black, Bonnie K et al. (2017) Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a 'sit-to-stand test'. J Hypertens 35:1019-1025
Kawai, Vivian K; Levinson, Rebecca T; Adefurin, Abiodun et al. (2017) Variation in the ?2A-adrenergic receptor gene and risk of gestational diabetes. Pharmacogenomics 18:1381-1386
Arnold, Amy C; Garland, Emily M; Celedonio, Jorge E et al. (2017) Hyperinsulinemia and Insulin Resistance in Dopamine ?-Hydroxylase Deficiency. J Clin Endocrinol Metab 102:10-14
Biaggioni, Italo (2017) The Pharmacology of Autonomic Failure: From Hypotension to Hypertension. Pharmacol Rev 69:53-62
Mai, Tu H; Garland, Emily M; Diedrich, André et al. (2017) Hepatic and renal mechanisms underlying the osmopressor response. Auton Neurosci 203:58-66
Kawai, V K; Levinson, R T; Adefurin, A et al. (2017) A genetic risk score that includes common type 2 diabetes risk variants is associated with gestational diabetes. Clin Endocrinol (Oxf) 87:149-155

Showing the most recent 10 out of 315 publications